CD39 on CD8 + Tumour‐Infiltrating Lymphocytes: A Paradoxical Marker of Tumour Reactivity and Immunosuppression
European Journal of Immunology · 2026-10 · 56 (10)
DOI: 10.1002/eji.70288 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Immunology, online erschienen am 08.10.2026. Verfasst von Manolo Sambucci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Medical Specialities (DIMI), University of Genova, Genoa, Italy. Hauptthemen laut MEDLINE: Apyrase, Lymphocytes, Tumor-Infiltrating, Neoplasms, CD8-Positive T-Lymphocytes. Die Arbeit nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
CD39 (ENTPD1) occupies a paradoxical position in the immunology of solid tumours. On CD8 + tumour‐infiltrating lymphocytes (TILs), its surface expression serves as one of the most reliable available markers of genuine tumour‐antigen experience and identifies the clonally expanded tissue‐resident and cytolytically competent T cells, that are largely absent from the bystander populations, which are specific for tumour‐unrelated antigens and numerically dominate many tumour infiltrates. Yet the same enzymatic activity that defines CD39, the hydrolysis of extracellular ATP (eATP) to AMP, directly feeds CD73‐dependent adenosine generation. These very cells therefore actively perpetuate the immunosuppressive purinergic milieu that constrains their own effector function and that of surrounding immune cells. CD39 + CD8 + TILs thus represent simultaneously the best cellular evidence that a productive anti‐tumour immune response has occurred, and among the most potent local drivers of its suppression. This review places this paradox at its centre, dissecting the molecular basis of CD39 expression, its two opposing functional identities across solid tumour types and the therapeutic logic that follows: Blocking CD39 activity could simultaneously release the suppressive brake and preserve the tumour‐reactive cells that express it.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Medical Specialities (DIMI), University of Genova, Genoa, Italy.
- Neuroimmunology Unit, LIFE Institute for Research and Health Care - Santa Lucia IRCCS, Rome, Italy.
- Biotherapy Unit, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy.
- Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy.
ORCID-Profile: Manolo Sambucci, Daniela Fenoglio, Andrea Lagazio, Giovanna Borsellino, Gilberto Filaci
Zitieren
APA
Sambucci, M., Fenoglio, D., Ferrera, F., Camporesi, L., Lagazio, A., Borsellino, G., Battistini, L., & Filaci, G. (2026). CD39 on CD8 + Tumour‐Infiltrating Lymphocytes: A Paradoxical Marker of Tumour Reactivity and Immunosuppression. European Journal of Immunology, 56(10). https://doi.org/10.1002/eji.70288
Vancouver
Sambucci M, Fenoglio D, Ferrera F, Camporesi L, Lagazio A, Borsellino G, et al. CD39 on CD8 + Tumour‐Infiltrating Lymphocytes: A Paradoxical Marker of Tumour Reactivity and Immunosuppression. European Journal of Immunology. 2026;56(10). doi:10.1002/eji.70288
BibTeX
@article{Sambucci2026,
author = {Sambucci, Manolo and Fenoglio, Daniela and Ferrera, Francesca and Camporesi, Laura and Lagazio, Andrea and Borsellino, Giovanna and Battistini, Luca and Filaci, Gilberto},
title = {CD39 on CD8 + Tumour‐Infiltrating Lymphocytes: A Paradoxical Marker of Tumour Reactivity and Immunosuppression},
journal = {European Journal of Immunology},
year = {2026},
volume = {56},
number = {10},
doi = {10.1002/eji.70288}
}
EUVIMED